Supplementary Files
Categories
How to Cite
Abstract
Renal denervation (RDN) is a minimally invasive procedure by which ultrasound guided ablation or radiofrequency ablation is used to target sympathetic nerves within the walls of renal arteries causing a decrease in their activity and consequently, a reduction in the patient’s blood pressure. Although RDN has emerged as a novel therapy for the treatment of resistant hypertension (HTN), its indication spectrum and new therapeutic options are still broadening. HTN remains the main risk factor for the development and maintenance of many cardiovascular diseases including AF. Therefore, initial findings suggest that renal artery ablation proposes to be an innovative intervention in the treatment of AF through the precise targeting of efferent sympathetic and afferent sensory renal nerve signaling, selectively ablating the renal sympathetic nerves. Nevertheless, the efficacy and long-term results of RDN continues to be the focus of ongoing investigation and exploration.
References
Denker MG, Cohen DL: Resistant Hypertension and Renal Nerve Denervation. Methodist Debakey Cardiovasc J. 2015, 11:240-244. 10.14797/mdcj-11-4-240
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010, 376:1903-1909. 10.1016/s0140-6736(10)62039-9
Bhatt DL, Vaduganathan M, Kandzari DE, et al.: Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022, 400:1405-1416. 10.1016/s0140-6736(22)01787-1
Bhatt DL, Kandzari DE, O'Neill WW, et al.: A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine. 2014, 370:1393-1401. 10.1056/NEJMoa1402670
Versaci F, Sciarretta S, Scappaticci M, et al.: Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation. European Heart Journal Supplements. 2021, 23:E177-E183. 10.1093/eurheartj/suab117
Romanov A, Pokushalov E, Ponomarev D, et al.: Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor. Cardiovascular Therapeutics. 2017, 35:e12264. https://doi.org/10.1111/1755-5922.12264
Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M: Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol. 2014, 63:215-224. 10.1016/j.jacc.2013.09.020
Sankaranarayanan R, Kirkwood G, Dibb K, Garratt CJ: Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. Cardiol Res Pract. 2013, 2013:976976. 10.1155/2013/976976
Shen MJ, Zipes DP: Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014, 114:1004-1021. 10.1161/circresaha.113.302549
Chen PS, Tan AY: Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007, 4:S61-64. 10.1016/j.hrthm.2006.12.006
Sharifov OF, Fedorov VV, Beloshapko GG, Glukhov AV, Yushmanova AV, Rosenshtraukh LV: Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol. 2004, 43:483-490. 10.1016/j.jacc.2003.09.030
Pokushalov E, Romanov A, Corbucci G, et al.: A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012, 60:1163-1170. 10.1016/j.jacc.2012.05.036
Viskin S, Golovner M, Malov N, et al.: Circadian variation of symptomatic paroxysmal atrial fibrillation. Data from almost 10 000 episodes. Eur Heart J. 1999, 20:1429-1434. 10.1053/euhj.1999.1632
Carnagarin R, Kiuchi MG, Ho JK, Matthews VB, Schlaich MP: Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. Front Neurosci. 2018, 12:1058. 10.3389/fnins.2018.01058
Zimetbaum P: Antiarrhythmic Drug Therapy for Atrial Fibrillation. Circulation. 2012, 125:381-389. doi:10.1161/CIRCULATIONAHA.111.019927
Calkins H, Brugada J, Packer DL, et al.: HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007, 9:335-379. 10.1093/europace/eum120
Nawar K, Mohammad A, Johns EJ, Abdulla MH: Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis. Journal of Human Hypertension. 2022, 36:887-897. 10.1038/s41371-022-00658-0
Townsend RR, Mahfoud F, Kandzari DE, et al.: Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017, 390:2160-2170. 10.1016/s0140-6736(17)32281-x
Lau YF, Yiu KH, Siu CW, Tse HF: Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens. 2012, 26:563-569. 10.1038/jhh.2011.105
Mahfoud F, Townsend RR, Kandzari DE, et al.: Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. J Am Coll Cardiol. 2021, 77:2909-2919. 10.1016/j.jacc.2021.04.044
Thomas MC, Dublin S, Kaplan RC, et al.: Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008, 21:1111-1116. 10.1038/ajh.2008.248
Feyz L, Theuns DA, Bhagwandien R, et al.: Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study. Clin Res Cardiol. 2019, 108:634-642. 10.1007/s00392-018-1391-3
Romanov A, Pokushalov E, Ponomarev D, et al.: Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor. Cardiovasc Ther. 2017, 35. 10.1111/1755-5922.12264
Sohinki D, Stavrakis S: New approaches for treating atrial fibrillation: Focus on autonomic modulation. Trends in Cardiovascular Medicine. 2020, 30:433-439. https://doi.org/10.1016/j.tcm.2019.10.009
Vollmann D, Sossalla S, Schroeter MR, Zabel M: Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation. Clin Res Cardiol. 2013, 102:315-318. 10.1007/s00392-012-0529-y
Younis A, Steinberg JS: Renal Denervation for Patients With Atrial Fibrillation. Curr Cardiol Rep. 2021, 23:126. 10.1007/s11886-021-01558-4
Schmieder RE: Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrology Dialysis Transplantation. 2022, 38:1089-1096. 10.1093/ndt/gfac189
Rey-García J, Townsend RR: Renal Denervation: A Review. American Journal of Kidney Diseases. 2022, 80:527-535. https://doi.org/10.1053/j.ajkd.2022.03.015
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 High Yield Medical Reviews